Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRTA Stock Forecast 2026-2027
$8.66
Current Price
$443.43M
Market Cap
Buy 3
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PRTA Price Targets
+315.7%
To High Target of $36.00
+130.9%
To Median Target of $20.00
-7.6%
To Low Target of $8.00
PRTA Price Momentum
-6.3%
1 Week Change
-3.0%
1 Month Change
+38.3%
1 Year Change
-9.3%
Year-to-Date Change
-26.6%
From 52W High of $11.80
+38.8%
From 52W Low of $6.24
📊 TOP ANALYST CALLS
Did PRTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prothena is one of their latest high-conviction picks.
Latest PRTA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PRTA has a neutral consensus with a median price target of $20.00 (ranging from $8.00 to $36.00). The overall analyst rating is Buy (7.0/10). Currently trading at $8.66, the median forecast implies a 130.9% upside. This outlook is supported by 3 Buy, 2 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRTA Analyst Ratings
3
Buy
2
Hold
1
Sell
PRTA Price Target Range
Low
$8.00
Average
$20.00
High
$36.00
Current: $8.66
Latest PRTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Citizens | Jason N. Butler | Market Outperform | Maintains | $20.00 |
| Feb 20, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Dec 1, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Nov 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 7, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Oct 28, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 2, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Aug 28, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 28, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 5, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Aug 5, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 5, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 20, 2025 | Cantor Fitzgerald | Neutral | Reiterates | $N/A | |
| May 28, 2025 | B of A Securities | Underperform | Downgrade | $N/A | |
| May 27, 2025 | Oppenheimer | Perform | Downgrade | $N/A | |
| May 27, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 27, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| May 27, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 27, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Prothena Corporation plc (PRTA) Competitors
The following stocks are similar to Prothena based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prothena Corporation plc (PRTA) Financial Data
Prothena Corporation plc has a market capitalization of $443.43M with a P/E ratio of -1.9x. The company generates $57.94M in trailing twelve-month revenue with a -260.9% profit margin.
Revenue growth is +1,706.4% quarter-over-quarter, while maintaining an operating margin of +50.5% and return on equity of -40.3%.
Valuation Metrics
Market Cap
$443.43M
Enterprise Value
$119.53M
P/E Ratio
-1.9x
PEG Ratio
0.0x
Price/Sales
7.7x
Growth & Margins
Revenue Growth (YoY)
+1,706.4%
Gross Margin
N/A
Operating Margin
+50.5%
Net Margin
-260.9%
EPS Growth
+1,706.4%
Financial Health
Cash/Price Ratio
+72.7%
Current Ratio
10.4x
Debt/Equity
2.4x
ROE
-40.3%
ROA
-13.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prothena Corporation plc (PRTA) Business Model
About Prothena Corporation plc
What They Do
Biotechnology company developing therapies for neurodegenerative diseases.
Business Model
Prothena Corporation focuses on creating novel therapies that target protein dysregulation, primarily for neurodegenerative and rare diseases. The company generates revenue through collaborations and partnerships with major pharmaceutical firms, such as Roche and Novo Nordisk, allowing it to advance its clinical programs and share development costs.
Additional Information
Founded in 2012 and based in Dublin, Ireland, Prothena has a robust pipeline featuring several key programs in various stages of clinical trials. Their innovative platforms and strategic collaborations position them as leaders in neuroscience, aiming to provide transformative treatments for conditions with significant unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
67
CEO
Dr. Gene G. Kinney Ph.D.
Country
Ireland
IPO Year
2012
Website
www.prothena.comProthena Corporation plc (PRTA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
Jul 09, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Prothena shares rise due to advancements in late-stage programs, strengthened finances from milestone payments, and an expanding neurodegenerative pipeline.
Why It Matters
Prothena's share price increase signals investor confidence, driven by advancing programs and financial stability, which could lead to future growth and profitability in the neurodegenerative sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Biomedical and Genetics sectors are comparing Sarepta Therapeutics (SRPT) and Prothena (PRTA) for potential value investment opportunities.
Why It Matters
The comparison between Sarepta Therapeutics and Prothena highlights potential investment opportunities in the biomedical sector, signaling value investor interest and implications for stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Prothena reported its Q1 2026 financial results and business highlights today. Further details were not specified in the excerpt.
Why It Matters
Prothena's Q1 2026 financial results and business highlights could indicate growth potential, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PRTA reported a Q1 profit, driven by a $50M milestone payment from Novo Nordisk, enhancing its cash outlook for 2026.
Why It Matters
PRTA's Q1 profit from the Novo Nordisk milestone enhances revenue and strengthens its 2026 cash outlook, signaling growth potential and financial stability, which can attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Prothena will report its Q1 2026 financial results on May 7, 2026, after the U.S. markets close.
Why It Matters
Prothena's upcoming financial results may signal its performance and market position, influencing investor sentiment and stock valuation ahead of the announcement.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Prothena's coramitug (PRX004) has received Fast Track Designation from the U.S. FDA for treating ATTR amyloidosis with cardiomyopathy, as announced by Novo Nordisk.
Why It Matters
Novo Nordisk's Fast Track Designation for coramitug could accelerate its development and market entry, potentially increasing Prothena's valuation and attracting investor interest in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PRTA Stock
What is Prothena Corporation plc's (PRTA) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Prothena Corporation plc (PRTA) has a median price target of $20.00. The highest price target is $36.00 and the lowest is $8.00.
Is PRTA stock a good investment in 2027?
According to current analyst ratings, PRTA has 3 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $8.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRTA stock?
Wall Street analysts predict PRTA stock could reach $20.00 in the next 12 months. This represents a 130.9% increase from the current price of $8.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prothena Corporation plc's business model?
Prothena Corporation focuses on creating novel therapies that target protein dysregulation, primarily for neurodegenerative and rare diseases. The company generates revenue through collaborations and partnerships with major pharmaceutical firms, such as Roche and Novo Nordisk, allowing it to advance its clinical programs and share development costs.
What is the highest forecasted price for PRTA Prothena Corporation plc?
The highest price target for PRTA is $36.00 from at , which represents a 315.7% increase from the current price of $8.66.
What is the lowest forecasted price for PRTA Prothena Corporation plc?
The lowest price target for PRTA is $8.00 from at , which represents a -7.6% decrease from the current price of $8.66.
What is the overall PRTA consensus from analysts for Prothena Corporation plc?
The overall analyst consensus for PRTA is neutral. Out of 2 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $20.00.
How accurate are PRTA stock price projections?
Stock price projections, including those for Prothena Corporation plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:50 AM UTC